Dosage Forms

Homogeneity of the powder blend is crucial for solid-dosage drug manufacturing.

Complex and potent molecules demand greater technical and regulatory expertise to ensure safe handling.

Glass vials have come a long way from mere commodities and are now considered an integral part of final drug product.

Formulators of parenteral drugs must be cautious of specific considerations and challenges that arise during development and manufacture.

As patient-centered therapies and clinical trials become more important, innovation is providing more control and transparency in the way that pharmaceuticals are delivered.

Industry experts discuss the role of gene-editing techniques in regenerative medicine and cell-line development.

Biopharma industry faces production challenges as gene therapies move from clinical to commercialization.

Mass-produce cell and gene therapies presents the biopharma industry with a unique set of challenges.

Researchers in China are playing a role in advancing gene therapy development.

Daiichi Sankyo Europe has revealed the results of a Phase III study assessing the efficacy, safety, and tolerability of bempedoic acid/ezetimibe fixed-dose combination (FDC) tablet.

Neuraxpharm Group has announced it is launching its first products in the United Kingdom.

Iontas and Teva Pharmaceuticals have entered into an agreement for the application of technologies and know-how into the optimization of human antibodies to be used as biotherapeutics.

Cure Pharmaceutical secured a patent that lets the company load higher drug amounts to its proprietary drug delivery system, CUREfilm.

Lonza plans to implement MES software to accelerate paperless, 24/7 production of drug capsules.

Suheung’s new facility in Vietnam is dedicated to vegetarian capsule manufacturing.

An agreement with Sanofi gives Catalent access to commercial spray drying facility in Haverhill, UK.

Several trends are driving change in oral solid‑dosage forms and giving rise to the requirement of ‘fit-for-purpose’ excipients.

More than 30 lots of losartan drug products have been recalled due to contaminated API manufactured by Hetero Labs.

Novavax will sell two Maryland-based vaccine development and manufacturing facilities for Catalent’s expanding gene therapy footprint.

Two additional production lines expand Lonza’s HPAPI capacity at Visp, Switzerland facility.

Tergus Pharma announced a partnership with Great Point Partners and construction of a new commercial manufacturing facility in North Carolina.

European midmarket private equity group, Duke Street, has agreed to acquire Kent Pharmaceuticals and Athlone Laboratories from DCC Vital.

A simple, one-part DPI aims to make inhalation drug treatment more accessible and affordable.

Excipients and new processing techniques can make a real difference in the development of highly potent therapies.

Wearable and smart devices allow user-friendly subcutaneous drug delivery.

Expanded controlled substance capabilities enables Particle Sciences to develop and manufacture Schedule I–V drugs.

Catalent expands gene therapy capabilities with $1.2-billion acquisition of Paragon Bioservices.

StarTab from Colorcon was designed to ensure functionality and stability for direct compression tableting.

Consider both the device characteristics and the powder properties when developing a DPI combination product.

Empty and prefilled syringes must pass a range of quality control tests.